View all veterinary jobs
VetSurgeon.org publishes a curated feed of veterinary news for practising veterinary surgeons, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest, or professional significance — filtering out noise so busy vets can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, farm, equine and exotic species.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetSurgeon News by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
The improvements include a new cat ward designed to offer a quieter, more relaxing area away from other animals, and a new walk-in dog ward which will allow staff to treat larger breeds of dogs more easily. The intensive care unit has been expanded and the practice has developed a new chemotherapy area.
John Turkington, the partner at Scarsdale Vets responsible for overseeing the work said: "We are already really proud of the state-of-the-art facilities we have at Pride, but we are not complacent and that is why we have made this significant investment to improve our facilities and ultimately the services we offer our clients and patients. Patient comfort is paramount, which is why we’ve invested in an additional walk in ward for our larger breeds, and a new cat ward with a separate feline examination and treatment area."
As well as the changes to improve clinical care, the practice has also invested in its kennelling services, increasing the number of 'suites' for cats and dogs to stay in its 'hotel' areas whilst their owners go on holiday.
John added: "We want Pride to be recognised as one of the best veterinary hospitals in Europe and to make that a reality we have increased our ward capacity for patient comfort and clinical treatment areas, as well as improving facilities behind the scenes for our staff, to create a better working environment. Alongside that the improvements to our Pet Resort will also meet the growing demands from clients for those services."
'FLUTD and Dysuria – a frustration for many and not just the cat' will be presented by Dr Hanne Friis Lund (DVM) from Idexx and Katy Smith from Royal Canin (pictured right).
Hanne will be talking about diagnostics, focusing on urine analysis and laboratory tests, whilst Katy will discuss nutritional management of the condition.
Hanne said: "Feline lower urinary tract disease is a very common condition in both male and female cats affecting 1-3% of cats every year.
"It goes without saying that FLUTD causes great discomfort and pain for the feline, which is why the webinar will explore how best to manage the condition from a nutritional point of view.
"From the innovative Haematuria Detection by Blücare litter granules which turn blue when a urinary condition is detected to the new urinary range kibble from Royal Canin’s Veterinary Health Nutrition, the webinar will be leaving no stone unturned."
To register for the webinar, go to: https://vetportal.royalcanin.co.uk/cpd/webinar/
The two 60-minute interactive sessions are taking place on Wednesday (21st April) at 12.30pm and 6pm, coinciding with the United Nation’s World Creativity and Innovation Day.
Each session will introduce a range of creative techniques that can be used to spur innovation. Different breakout groups will then have various problems to solve and will utilise these techniques to tackle challenges and issues encountered within everyday veterinary practice.
Sophie Rogers, RCVS ViVet Manager, said: "These creativity techniques are a framework for approaching problems, but the key to developing solutions to everyday tasks and problems is learning how to foster and harness the whole team's creative abilities. These workshops will provide the techniques to help you and your team overcome the common barriers to creativity and gain the tools and mindsets needed to break existing patterns and ways of doing things, generate new ideas, and improve creative self-leadership.”
The workshops will be hosted by Gill Stevens (pictured right), the Founding Director of Level Seven, a consultancy that specialises in merging coaching with design thinking methodology as a way to support innovation and team productivity, and Rick Harris, Founder of Customer Faithful, a research-led consultancy, specialising in customer research, proposition design and employee engagement.
Veterinary professionals can sign up to the sessions, which count towards their continuing professional development (CPD) requirement, via the ViVet website at: www.vivet.org.uk/interactive-workshop-on-creative-thinking/
The company says its new design is modular, allowing veterinary practices to customise kennels to their requirements now, and then upgrade them and add components as their needs change over time.
Options include dimmable daylight lighting or Casco Pet’s DRC Lighting System with three modes: Daylight (white), Recovery (red), and Cleaning (blue UVA), built-in thermostatically controlled heat mats, an illuminated glass whiteboard for easy recording and viewing of patient notes, integrated IV stand and pump holders, an internal ceiling vent and ventilation kit and an integrated plug socket and USB port .
Matthew Bubear, CEO, Casco Pet, said: “Our new generation of WellKennels, which have been designed to meet the dynamic demands of modern veterinary practices, allow practitioners to elevate the care they provide today while ensuring sustained adaptability for the needs of tomorrow."
WellKennels are certified by the International Society of Feline Medicine and are part of FearFree’s Preferred Product Program, the global initiative dedicated to preventing and alleviating fear, anxiety and stress in pets.
The new WellKennels will be unveiled at the London Vet Show, ExCel London, 16-17 November, on Stand H35.
https://cascopet.com/uk/products-and-services/veterinary
Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
The updated indications reflect the recognition that Stelfonta may be used in any case where surgery may not be an option:
For the treatment of non-metastatic (WHO staging) mast cell tumours that are either non-resectable or those that are resectable but where surgery is not considered the best option, specifically: cutaneous mast cell tumours (located anywhere on the dog) and subcutaneous mast cell tumours located at or distal to the elbow or the hock.
Tumours must be less than or equal to 8 cm 3 in volume, and must be accessible to intratumoral injection.
Neil Mottram MRCVS, Technical Manager at Virbac said: “Stelfonta offers veterinary surgeons a medical option for the successful elimination of mast cell tumours.
"The extended labelled indication demonstrates the wide variety of cases that can benefit where medical treatment is preferred, such as; tumour factors (location and size) making surgical margins difficult, patient factors (concurrent disease and risk of anaesthesia), clinic factors and the simplification of this medical treatment and owner factors, where there is a preference to avoid surgery."
Stelfonta is administered by injection directly into the tumour mass and Virbac say that generally, dogs do not require sedation or local or general anaesthesia during treatment.
The active ingredient, Tigilanol tiglate, works largely through specific protein kinase c (PKC) activation, in which it locally stimulates the immune system, resulting in destruction of the tumour and the tumour’s blood supply, followed by rapid healing of the site with minimal scarring.
www.virbac.co.uk
Dr Kalisz faced a total of nine charges (including 41 sub-charges).
The first was that in July 2020, she failed to carry out a clinical examination of the dog, failed to adequately interpret test results, failed to ask for help interpreting the results, and undertook an emergency Caesarean section without sufficient need to do so.
The other charges related to undertaking a colotomy without sufficient justification and without exercising sufficient clinical judgment throughout the procedure.
For both the Caesarean section and the colotomy, Dr Kalisz faced charges that she failed to obtain informed consent from the owners and failed to inform them that the colotomy had been carried out, or of the potential risks of the procedure, and also failed to provide enough information about aftercare.
It was also alleged that Dr Kalisz had demonstrated continual lapses in professional judgement, including failing to appropriately manage the spaniel’s worsening condition when it was presented to the practice again later, and that the clinical records in relation to the surgery were dishonest and/or misleading.
Dr Kalisz admitted serious professional misconduct, admitting to 29 of the sub-charges, while the remaining 12 sub-charges were denied.
The Committee found 30 of the sub-charges proven, with the remaining 11 not proven.
The Committee the considered aggravating factors, including the fact that Dr Kalisz's conduct led to the spaniel’s death, the colotomy was reckless and Dr Kalisz did not take steps to inform anybody or make a clinical record for the colotomy.
In mitigation, the Committee considered the fact that it was single and isolated incident (albeit one that spanned a number of days), that no other members of the clinical team involved raised concerns during the procedure, and the effect Covid had upon the veterinary profession.
The Committee found that of those charges proven, the ones relating to performing the colotomy, failing to manage the spaniel’s subsequent care and failing to mention the colotomy amounted to serious professional misconduct.
On deciding the sanction, the Committee took into account the mitigation submitted on behalf of Dr Kalisz and the written testimonials produced including the fact that she was young and inexperienced, had admitted her failings at an early stage, had made subsequent efforts to avoid a repetition of such behaviour and that a significant amount of time had passed since the incident.
The Committee also considered that Dr Kalisz had shown an exemplary level of insight, showing remorse for her actions, undertaking substantial continuing professional development, and finding appropriate ongoing professional mentorship.
The Committee was impressed by the character testimonials from veterinary co-workers, both current and at the time of these events, as well as from clients.
It was, the Committee said, apparent from those testimonials that Dr Kalisz had been open and honest with them about the charges and was considered to be an excellent, committed veterinary surgeon.
Paul Morris, chairing the Committee and speaking on its behalf said: “The Committee found that this was a single isolated incident, which involved serious lapses of clinical judgement.
"It was therefore concluded that, despite Dr Kalisz’s actions being reckless, the extensive mitigation and the high level of insight, coupled with steps taken to avoid repetition, meant that there was negligible future risk to animal welfare.
“The Committee did not consider it necessary to issue a warning to Dr Kalisz about her future conduct, on the basis that the Committee has concluded that there is little risk of repetition, so considered that a reprimand would be an appropriate sanction in this case.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.
The solution, which Virbac says can also help eliminate bad breath, has been given a fresh new blue colour as well as a new bottle with a more contemporary design.
Claire Lewis, Junior Product Manager at Virbac, said: "Vet Aquadent is tried and trusted by many pet owners and relied upon for the contribution it makes to maintaining oral and dental health in dogs and cats.
"Blue is a popular colour in the veterinary dental sector so we wanted to bring Vet Aquadent in line with other related products to help ensure that it is instantly recognisable, both to existing and new users.
"It sits alongside the other products in our ‘at-home’ veterinary dental range, including our Enzymatic toothpastes which inhibit bacterial growth and our highly palatable VeggieDent chews, which are available in four sizes."
"Given the number of pets suffering from periodontal disease, encouraging pet owners to adopt an effective preventative care regime is a simple way for veterinary practices to encourage responsible pet ownership and, in so doing, generate a useful revenue stream from product sales."
1243 farmers took part in the survey, which was held in partnership with the National Beef Association, British Dairying magazine, the relevant farming unions and the four eradication programmes.
Matt Yarnall from Boehringer said: "Reliance on veterinary input for this decision shows how valuable client discussion and guidance is. And further interrogation of the data shows other areas of BVD control where veterinary input could be extremely valuable.
"Too many producers are still holding onto PI animals in the hope they can be reared successfully and too many are making basic mistakes when it comes to herd biosecurity.
"The survey data revealed that 43% of farmers in Wales have identified a PI, but it is hugely concerning that almost half (42%) of these producers would not cull them immediately; these animals will go on to spread virus throughout the herd."
In Northern Ireland, 26 individual producers said they have kept a PI. "However, 20 had to be put down before reaching adulthood or had to be treated for other health conditions," said Matt. "Even in Scotland, with its well-established scheme, a small percentage of farmers claim they would isolate a PI and try to rear to slaughter and it was exactly the same in England."
Similarly, when it came down to the definition of a closed herd, Boehringer reports that there was significant lack of understanding about what this actually means.
Matt said: "Of the 62% of English producers that state they are closed herds, 2% rear calves away, 19% bring bulls in, 2% buy in heifers or cows and 1% purchase fattening stock.
"Obviously, this means they are not truly a closed herd and supports previous years when 23% and 24% of ‘closed herd’ producers in 2018 and 2017 respectively also brought bulls onto the farm.
"Add to this that 10% of these herds do not currently vaccinate so will not be protected against the BVD virus, and it is clear to see how vulnerable they are."
In Wales, 56% of herds were classified as closed, yet 12% still brought bulls on to the farm. Likewise in Northern Ireland, 60% of farms classified their herds as closed but 20% brought bulls on to the unit. The vast majority of Scottish herds also claimed to be closed, yet there were still inconsistencies around buying policy and biosecurity.
Matt said: "A certain lack of awareness about both the BVD Stamp it Out initiative and Gwaredu BVD schemes (43% English and 27% of Welsh producers respectively claimed to have no knowledge of these programmes) could actually be a positive for vets. It could be the perfect opportunity to engage in proactive conversations with clients, covering issues such as testing, PI removal and biosecurity."
The aim of the survey, which closes on 16th June, is to recognise and help raise awareness of the multiple challenges faced by veterinary surgeons undertaking roles for Government as a distinct subset of the veterinary profession.
The Association of Government Veterinarians says that following the survey, it'll be producing a report which identifies issues which affect government vets' wellbeing, identifies existing tools to promote wellbeing within Government and considers developing new ones if necessary. It will also consider best practice and any gaps in the wellbeing services currently available that vets in Government roles would benefit from.
To take part in the survey, visit: https://www.surveymonkey.co.uk/r/vetswellbeing
You can read more about the survey here: https://vets.blog.gov.uk/2018/04/06/how-are-you-feeling-association-of-government-vets-wellbeing-survey-launched/
Photo: Christine Middlemiss introduces the survey.
The competition is open to all UK-based undergraduate veterinary students and offers them the opportunity to work as a team to brainstorm, develop and present an innovative idea to a board of industry professionals.
Students can enter either as a single applicant or as a group (of roughly five members), with single applicants then being placed in a group with other applicants from their university. There can be more than one team representing each university.
Each student’s project can cover any aspect of veterinary health innovation. The RCVS suggests potential projects might include: innovations within veterinary education, innovations to improve sanitation and hygiene, innovations to improve veterinary-public communication and innovations to improve patient safety.
Entries must show how they have improved upon – or extended beyond – current expectations of best practice in their chosen area.
Each applicant will receive support from one of the Association of Veterinary Students’ (AVS) Vet Futures Ambassadors, as well as a mentor session with a chosen industry professional to guide them on their project.
Teams will need to submit three components for judging: a log of their progress throughout the project (which can include social media updates using the hashtag #ViVetStudentInnovation), mentor engagement and feedback, and a five-minute video ‘business pitch’.
The three finalist groups of the competition will be invited to present their pitch to a board of industry professionals at a ‘Dragon’s Den’ style event held at the RCVS ViVet 2019 Innovation Symposium on Tuesday 1 October 2019 in Manchester.
The winning and runner-up groups will then be selected and will be presented alongside the ‘mentor’s choice’ award. The Mentor’s Choice award will be selected by the team mentors. The prize will be awarded to an individual who shows excellence and enthusiasm within their work on the project.
Anthony Roberts, RCVS Director of Leadership & Innovation (pictured right), said: "This competition provides a great opportunity for veterinary students to engage with their fellow classmates across different fields of study and to work on projects that could genuinely make a difference to animal health and welfare and the way veterinary services are delivered. Teams will receive one-on-one mentoring and will be guided through the innovation process, developing skills that will be useful throughout their careers. We look forward to seeing the three finalist teams presenting at the RCVS ViVet Innovation Symposium in Manchester on 1 October."
Zoe Skinner, Vet Futures Student Representatives Team Leader, said: “This competition is a great opportunity for veterinary students to receive mentoring from experienced veterinary professionals and form contacts within our profession. It gives students a way to work together as a team and allows them to learn how to produce and develop innovative, problem-solving concepts as well as skills in delivering presentations. These are all important aspects of our career ahead, which will look brilliant on our CV’s.”
ViVet is now accepting registrations for the competition for the 2018/19 academic year. To enter, applicants must submit an online registration form. For further information, email info@vivet.org.uk.
Krka says the new pack, available for cats and for toy, small, medium and large dogs, is designed to offer practices greater dispensing flexibility and to encourage quarterly visits and compliance with healthcare plans.
Selehold is presented in a pipette with a colour-coded cap and transparent tube to enable the owner to check when the full dose has been given. Each pipette is individually wrapped for ease of use and dispensing.
Ms Sabrina Jordan, Country Brand Manager for Krka, said: "We aim to optimise the value we give to our customers by offering them highly effective, tried and trusted, affordable generic medicines with added value.
"Selehold has proved a popular addition to our parasite control range because of its ease of use and cost-effectiveness.
"With many of our customers focusing on encouraging owners to visit the practice quarterly and to sign up to a healthcare plan for their pet, the 3-pack version of Selehold works well as it enables the practice to offer clients a high quality, good value solution that supports this compliance framework."
In the past, all practices that offered Carefree Credit to clients had to complete the FCA authorisation process, something which involved completing a 48 page online application and a wait of 12 weeks for approval. Although Carefree Credit provides guidance with the process and around 700 practices have enrolled successfully, it was not the ideal solution for practices who wanted a quick solution.
From now on, those practices that are happy to offer interest-free credit for a maximum period of 12 months can do so without going through the FCA process.
Stewart Halperin MRCVS, the founder of Carefree Credit, said: "For those of you who have looked at a client finance option for your practice but have been put off by the thought of going through the FCA authorisation process, this will make things much easier."
For more information, visit www.carefreecredit.co.uk/
Bell Equine is one of the leading equine hospitals and was the first practice worldwide to install a standing MRI unit for horses.
CVS says the acquisition reflects its increased focus on equine practice, with further expansion of its Equine Division planned in the UK and Europe during 2017.
Equine Director Ben Jacklin said: "The acquisition of such an outstanding hospital is an exciting step for us. Bell Equine has always been at the forefront of the equine profession, both clinically and non-clinically, and as such it is a perfect match for the Equine Division of CVS."
Julian Samuelson, former managing director of Bell Equine, will continue in the role of Clinical Director. He said: "We are delighted to be joining forces with CVS and are very much looking forward to working closely with the Group to help realise the exciting potential of its equine ambitions. We look forward to the opportunity to continue to lead the profession, both within and outside CVS."
Probably the two most popular social media platforms for veterinary surgeons in the UK are Facebook (and its various veterinary groups) and VetSurgeon.org.
Facebook has the advantage that so many people use it to share photographs with family and friends, so they are already on the site and it is only a very short hop over to participate in a veterinary discussion group. That makes it an excellent way to get a broad opinion on almost any subject.
But, and it is a very big 'but', Facebook was never designed to be a platform for sharing clinical information or discussing cases. So, for example, you cannot see the professional qualifications of anyone contributing to the discussion unless they happen also to be your 'friend', so it can be hard to tell whether they have any idea what they're talking about, or are, in fact, the leading light.
There are various other aspects of Facebook that are problematic when it comes to clinical discussions, including the difficulty in referring back to useful information shared and the way in which 'me too' replies can drown out good quality information.
The survey aims to find out how much of a problem vets think these things are, whether certain groups within the profession could be better served by social media - for example those that may find it daunting asking for help in an online group, and what features vets would like VetSurgeon.org to invest in.
The survey can be completed anonymously, but if you give your name at the end, you'll be entered into a draw for a case of champagne (or equivalent).
Take part here: https://bit.ly/2lzzpy4
Please share this story amongst your colleagues!
BCF, Instrumentation Concept and VetSonic have collected 'VetSurgeon.org Best Stand Awards'; the first two at BEVA Congress and the latter at BCVA Congress.
Judging for the BEVA Congress awards was undertaken by members of BEVA Council. BCF picked up the Best Large Stand Award which was presented by outgoing President, Andrew Harrison.
Pictured left to right: BEVA President, Andrew Harrison, Gavin Mitchell and Carole Irvine of BCF, and John Alborough representing VetSurgeon.org.
Instrumentation Concept picked up the Best Shell Scheme Award
Pictured left to right: Outgoing BEVA President, Andrew Harrison; Tahir Afzac of Instrumentation Concept; John Alborough representing VetSurgeon.org, and Sheraz Ishaque of Instrumentation Concepts
At BCVA Congress, Vetsonic won the Best Stand Award.
Pictured left to right: Clare Walsh, Vetsonic Director; John Alborough, All Round Good Egg representing VetSurgeon.org; Gareth Hateley, then President BCVA and Sarah Vermont, Marketing Manager Vetsonic.
The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
The RCVS Disciplinary Committee has directed that the name of a Berkshire-based veterinary surgeon, previously convicted of four offences under the Animal Welfare Act 2006, should be removed from the RCVS Register of Veterinary Surgeons.
Dr Ohene-Gyan was convicted at Reading Magistrates Court on 13 June 2012 of offences involving causing unnecessary suffering to three dogs and a cat that he had treated whilst working at Woosehill Vets, Wokingham, between February and October 2011. These offences related to failing to provide adequate or appropriate veterinary care or treatment, or failure to investigate and address an animal's poor condition. He was sentenced to 21 weeks' imprisonment concurrently for each offence.
Dr Ohene-Gyan did not attend the one-day Disciplinary Committee hearing and was not represented, although College records showed that he was aware of the dates of the hearing, and had had opportunity to apply for an adjournment. In the absence of any known good reason for Dr Ohene-Gyan's non-attendance, the Committee concluded that it was in the interests of justice that the hearing go ahead.
In considering whether the Respondent's convictions made him unfit to practise as a veterinary surgeon, the Committee depended on the findings of the District Judge and the remarks she had made when sentencing. "I found as a matter of fact that some of your actions were taken simply to run up a bill for the owners of pets," she had said. "You were in a position of special responsibility, trusted by the owners of the animals to treat them appropriately and to alleviate their suffering. You ignored advice from staff. Several animals were affected by your cruel disregard of their welfare. Some of the cruelty arose due to your incompetence. You have demonstrated that you are not fit to be trusted with the care of animals."
The Disciplinary Committee Chairman, Professor Peter Lees, speaking on behalf of the Committee, said: "The Respondent's actions, motivated by financial gain, caused serious actual injury to the four animals over a prolonged period of time. Clients are entitled to expect that veterinary surgeons will treat animals in their care humanely and with respect, and make animal welfare their first priority. The Committee considers that the care described in the District Judge's findings demonstrated a total disregard for the professional responsibilities of a veterinary surgeon."
The Committee concluded that the removal of Dr Ohene-Gyan's name from the Register was the only appropriate and proportionate sanction in this case in order to protect the welfare of animals, maintain public confidence in the profession and uphold proper standards of conduct, and it directed the Registrar to do so.
'Otitis Externa: Understanding Ear Disease’ will be presented by RCVS Recognised Specialist in Veterinary Dermatology, Stephen Shaw BVetMed CertSAD DVD PhD PgCAP FHEA MRCVS (pictured).
Virbac says the webinar will explain how Cortotic can help you reduce antimicrobial use when treating otitis externa in dogs, whilst offering the same efficacy as a fixed-combination product.
https://bit.ly/CortoticWebinar
A campaign to reform English libel law to allow for robust criticism of scientific and medical claims without fear of legal action has been launched by journalist and author Simon Singh. It's a campaign which anyone working in the caring professions might wish to support.
The campaign comes as a consequence of legal action taken against Mr Singh by The British Chiropractic Association, which took exception (perhaps unsurprisingly) to an article he'd written in The Guardian. In the article, Mr Singh denounced claims on the BCA website that its members could use spinal manipulation to treat children with colic, ear infections, asthma, sleeping and feeding conditions, and prolongued crying as 'bogus', and criticised the BCA for 'happily promoting' these claims.
Out of curiosity, VetSurgeon rang the BCA press office this morning, and asked to be given the references for studies which it feels would support the original claims made on its site. Non have been forthcoming so far, which is a surprise. Under the circumstances, we'd have expected the BCA would have a raft of supporting evidence readily available.
But this isn't really about whether or not chiropractic works or not. The case seems to hinge upon whether Mr Singh's article implied that the BCA was being deliberately dishonest, or just delusional. He say's the latter. Unfortunately for him, Mr Justice Eady recently ruled the former, leaving Mr Singh with a bill for £100,000 worth of legal fees.
Mr Singh is to appeal. At stake is the freedom to be able to challenge scientific claims without fear of being sued. If you'd like to support this campaign, visit senseaboutscience.com and add your name to the 7000 others (including some pretty illustrious names) who have already done so.
The Royal College of Veterinary Surgeons (RCVS) has clarified the legal position regarding the disbudding of goats, following recent media reports concerning undercover filming on UK goat farms.
The carrying out of any activity which amounts to veterinary surgery is restricted to veterinary surgeons unless there is a suitable exemption that allows other people to do it. The removal of the horn-bud of goats (disbudding) is considered veterinary surgery under the provisions of the Veterinary Surgeons Act 1966 (the Act).
Schedule 3 of the Act provides certain exemptions to the restriction on carrying out veterinary surgery, such as those allowing veterinary nurses and student veterinary nurses to undertake any medical treatment or any minor surgery (not involving entry into a body cavity) in certain circumstances. However, Schedule 3 specifically provides that these exemptions do not allow non-veterinary surgeons to undertake the disbudding of goats, except the trimming of the insensitive tip of an in-growing horn which, if left untreated, could cause pain or distress.
There are no other Exemption Orders covering the disbudding of goats and therefore this procedure may only be undertaken by veterinary surgeons.
The Mutilations (Permitted Procedures) (England) Regulations 2007, the Mutilations (Permitted Procedures) (Wales) Regulations 2007 and the Prohibited Procedures on Protected Animals (Exemptions) (Scotland) Regulations 2007 all include disbudding of goats as a procedure which can be carried out for non-therapeutic reasons. However, this secondary legislation is subject to the restrictions in the Veterinary Surgeons Act 1966 and therefore disbudding of goats is restricted to veterinary surgeons.The Welfare of Animals (Permitted Procedures By Lay Persons) Regulations (Northern Ireland) 2012 currently include disbudding of goats as a procedure which may be carried out by non-veterinary surgeons. However, the Veterinary Surgeons Act 1966 applies to Northern Ireland and the Regulations are scheduled to be amended later in 2012. This will make it clear that only veterinary surgeons may disbud goats in the UK.
The secondary legislation in the UK does not explicitly require anaesthetic to be administered when disbudding goats. However, disbudding should be carried out by veterinary surgeons in accordance with good practice and in such a way as to minimise pain and suffering caused to the animal, which should include use of an anaesthetic.
In summary, only a veterinary surgeon may undertake the disbudding of goats and due to the nature of the procedure, veterinary surgeons disbudding goats should administer anaesthetic.
The decision comes after 13 dead wild birds were confirmed to have the virus in Warwickshire.
Last week 17 wild birds were tested positive in Dorset and 31 infected birds have now been identified at the Dorset site. At that time Defra responded by putting a local prevention zone in place and, now it is known the disease is not isolated to the Dorset site, the prevention zone has been extended across the country as a precautionary measure.
The prevention zone means bird keepers across the country must:
Those keepers who have more than 500 birds will need to take extra biosecurity measures that include restricting access to non-essential people, changing clothing and footwear before entering bird enclosures and cleaning and disinfecting vehicles.
The birds in Warwickshire are still being tested but it is expected that it will be the same H5N6 strain of bird flu that was found in the wild birds in Dorset and has been circulating wild birds across Europe. Public Health England have advised the risk to public health is very low with the Food Standards Agency also offering reassurance that bird flu does not pose a food safety risk for UK consumers. Defra has confirmed that the H5N6 strain is different to the strains which affected people in China last year.
Although it does not represent a threat to public, it is highly infectious and deadly to birds.
British Veterinary Association (BVA) President John Fishwick said: "I’d encourage vets to reassure their clients that this strain of Avian Influenza poses a very low risk to public health and the food chain. However, there is clearly a need to try to contain further spread of the disease, which has almost certainly come from migratory birds, and vets and poultry owners should follow the new prevention zone measures and remain vigilant for signs of bird flu."
British Veterinary Poultry Association (BVPA) President Phil Hammond added: "It’s really important that all bird keepers heed biosecurity advice issued by Defra, and maintain the highest biosecurity standards. Any suspicion of Avian Influenza should be reported to the APHA as soon as possible."
Up-to-date advice and guidance on Avian Influenza is available on the Gov.UK website, including how to spot it, what to do if you suspect it, and measures to prevent it:
https://www.gov.uk/guidance/avian-influenza-bird-flu#about-avian-influenza
For further advice on Avian Influenza contact the Defra Helpline on 03459 33 55 77.
Photo: Wild Birds, Shutterstock / aDam Wildlife
There were 22,000 nominations for this year's awards, which will be held at the Kimpton Clocktower Hotel in Manchester on 24th March.
Other finalists are:
Vet Nurse of the Year
Practice of the Year
Practice Support Staff of the Year
Practice Manager of the Year
James Barnes, head of sales and partnerships at Petplan, said: “We’re delighted to announce the finalists for this year’s Veterinary Awards.
"The awards celebrate the dedication and brilliant work carried out by some of the UK’s very best veterinary professionals.
"Congratulations to all the 2022 finalists on this fantastic achievement."
For further information on the awards visit www.petplanvet.co.uk.
Willows says it is currently the only centre in the UK to offer the procedure, and one of very few in the world.
Simon Swift, an RCVS and European specialist in small animal cardiology (pictured right), heads the cardiology team at Willows.
He said: “Transcatheter edge-to-edge mitral valve repair (TEER) is already considered an alternative to surgical repair in human patients and there have been some very promising early clinical results in dogs.
“The procedure is performed under general anaesthesia through a small incision in the chest wall.
“Access within the beating heart is achieved by a needle puncture at the apex of the heart which is highlighted by continuous X-ray images and an ultrasound of the heart via a probe placed in the oesophagus.
“This allows correct positioning of a V-clamp across the mitral valve to reduce the amount of leakage.
“It’s a procedure that delivers meaningful results and an improved quality of life and, because it’s a minimally invasive process, patients are typically discharged from hospital within two days.”
www.willows.uk.net